U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

  1. Home
  2. Vaccines, Blood & Biologics
  3. Blood & Blood Products
  4. Approved Blood Products
  5. Advate
  1. Approved Blood Products

STN: BL 125063
Proper Name: Antihemophilic Factor (Recombinant), Plasma/Albumin Free Method
Tradename: Advate
Manufacturer: Baxter Healthcare Corp, License #0140

Indication: 

  • An Antihemophilic Factor (Recombinant) indicated for:
    • Control and prevention of bleeding episodes in adults and children (0-16 years) with Hemophilia A.
    • Perioperative management in adults and children (0-16 years) with Hemophilia A.
    • Routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and children (0-16 years) with Hemophilia A.
  • Advate is not indicated for the treatment of von Willebrand disease.

Product Information

Supporting Documents

Related Information

  • FDA Online Label Repository
    Search this database for drug labeling and other information. The content has not been altered or verified by the FDA and may not be the labeling on currently distributed products or identical to the labeling that is approved.
Back to Top